Report LibraryAll Reports
Hepatocellular Carcinoma (HCC) KOL Interview - US, Northeast
September 11, 2023
This interview with a US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HCC. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include tislelizumab, camrelizumab, and rivoceranib.
This interview was conducted on 25 July 2023.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
|Indications Covered:||Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)|